Skip to contents
NHLBI Women's Health Initiative
Women's Health Initiative banner
 
 

WHI CONTACT

BROAD AGENCY ANNOUNCEMENT

WHI PARTICIPANT WEBSITE

WHI SCIENTIFIC RESOURCES WEBSITE

PRESS RELEASES

PUBLICATIONS

LEGACY CONFERENCE

WHI PARTICIPANT UPDATES

NHLBI POSTMENOPAUSAL HORMONE THERAPY

Estrogen-Alone Study

Estrogen-Plus-Progestin Study

DIETARY MODIFICATION TRIAL

CALCIUM and VITAMIN D TRIAL

OBSERVATIONAL STUDY

Q & As for WHI STUDY PARTICIPANTS

WHI Background and Overview

WHI Update

Why WHI?

WHI Community Prevention Study

Additional Resources

   

Updated 03/4/08
 

NEW INFORMATION

Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SAA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML, for the WHI Investigators. "Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin." JAMA 2008;299(9):1036-1045.

NHLBI Press Statement "WHI Follow-up Study Confirms Health Risks of Long-Term Combination Hormone Therapy Outweigh Benefits for Postmenopausal Women."

Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer RD, Gillian MA, Walsh BW, Chen C, McTiernan A, for the Women's Health Initiative Investigators. "Estrogen Plus Progestin and Breast Cancer Detection by Means of Mammography and Breast Biopsy." Arch Intern Med. 2008;168(4):370-377.


The Women's Health Initiative (WHI) was a major 15-year research program to address the most common causes of death, disability and poor quality of life in postmenopausal women -- cardiovascular disease, cancer, and osteoporosis.

Findings from the WHI Postmenopausal Hormone Therapy Trials

The WHI was launched in 1991 and consisted of a set of clinical trials and an observational study, which together involved 161,808 generally healthy postmenopausal women.

The clinical trials were designed to test the effects of postmenopausal hormone therapy, diet modification, and calcium and vitamin D supplements on heart disease, fractures, and breast and colorectal cancer.

The hormone trial had two studies: the estrogen-plus-progestin study of women with a uterus and the estrogen-alone study of women without a uterus. (Women with a uterus were given progestin in combination with estrogen, a practice known to prevent endometrial cancer.) In both hormone therapy studies, women were randomly assigned to either the hormone medication being studied or to placebo. Those studies have now ended. The women in these studies are now participating in a follow-up phase, which will last until 2010.


If you are a researcher and wish to explore the possibility of using WHI public-use data, please see The NHLBI Limited Access Dataset Program website for policy information. You can go directly to specific WHI information at WHI Limited Access Data Release.

If you wish to collaborate with a WHI investigator or are interested in applying for future Broad Agency Announcement (BAA) funding please visit the WHI Scientific Resources website.


 
 
Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute
Link to DHHS Link to NIH Link to NHLBI Link to DHHS